Impedimed Limited · ASX:IPD
Impedimed — Q4 FY25 Earnings Presentation
22 slides from Impedimed's earnings presentation, Jul 31, 2025
Slide 1: ASX cover letter: Investor Presentation
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 31 July 2025 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentation
Slide 2: Q4 FY25 Results
For personal use only Impedimed Limited Q4 FY25 Results July 2025 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: Agenda
Agenda For personal use only 1 Q4 Key Highlights 2 Business Overview 3 Financial Performance 4 H1 FY26 Outlook Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 3
Slide 5: Q4 Key Highlights
For personal use only Q4 Key Highlights Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 4 ©2025 ImpediMed Limited.
Slide 6: Q4 FY25 vs Outlook
Q4 FY25 vs Outlook ✓ Significant increase in US sales expected in Q4 and the balance of the 2025 calendar year: For personal use only ✓ Continue to initiate Lymphoedema awareness activities to generate leads ✓ Further measured investment to accelerate sales strategy ✓ Drive improvement in sales metr
Slide 7: Q4 Key Highlights
Q4 Key Highlights Financial • Record TCV $6.3m. For personal use only • Revenue $3.3m. • Annual recurring revenue $14.0m. • Quarterly operating cash outflow ($3.5m). • Qualified for US$5.0m Tranche 2 of US$15.0m growth capital facility. • Cash balance $22.2m, equating to 6.3 quarters of operating ca
Slide 8: Business Overview
For personal use only Business Overview Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 7 ©2025 ImpediMed Limited.
Slide 9: Sales
Sales Continued focus on accelerating BCRL For personal use only • Solid foundation set - ARR business model, 1,000+ devices deployed, leading US healthcare customers, NCCN & NAPBC guideline inclusions. • Reimbursement levels are improving and are sufficient to support sales needed to achieve Compan
Slide 10: Expanding reimbursement, robust pipeline, and strengthened sales team
Expanding reimbursement, robust pipeline, and strengthened sales team driving sustainable sales growth Reimbursement For personal use only 1 January 2025 1 July 2025 25 US states > 80% coverage 36 US states > 80% coverage 7 US states > 90% coverage 21 US states > 90% coverage Leads Opportunities Sal
Slide 11: Sustainable sales growth expected in FY26
Sustainable sales growth expected in FY26 Confident in delivering sustainable sales growth in FY26 For personal use only • Significantly larger pipeline from investment in systems & marketing • Increasing reimbursement - substantial increase from July 1, 2025 • Improvements in sales team • Appointme
Slide 12: Strategy
Strategy Achieve profitability through a focus on sales, marketing and clinical execution For personal use only Current priorities Achieve profitability Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Financial discipline Body Comp Develop new markets growth ex
Slide 13: Measured expansion into Body Comp initiated
Measured expansion into Body Comp initiated Body Comp opportunity Clinical guidelines recommending bioimpedance For personal use only • The global GLP-1 market, currently valued at around $52 billion, is • The Lancet Diabetes & Endocrinology Commission, May 2025 definition and experiencing rapid gro
Slide 14: Investigator led studies key to expanding in cardiology patients
Investigator led studies key to expanding in cardiology patients Heart Failure opportunity For personal use only • Heart failure affects more than 64M people world-wide1. In the US, currently 6.7M US patients, growing to 8.5M patients by 2030. • US outpatient heart failure fluid monitoring TAM estim
Slide 15: Financial Performance
For personal use only Financial Performance Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 14 ©2025 ImpediMed Limited.
Slide 16: Cash Flow
Cash Flow Summarized Cash Flow FY24 FY25 In thousands FY Q1 Q2 Q3 Q4 FY • Q4 operating cash outflow of $3.5m, in line with For personal use only AUD Actual Actual Actual Actual Actual Actual forecasts. Receipts from customers 11,493 2,718 3,419 4,059 3,784 13,980 Research & development (391) (88) (7
Slide 17: TCV and ARR
TCV and ARR SOZO Core Business Quarterly Total Contract Value1 SOZO Annual Recurring Revenue2 For personal use only A$ millions A$ millions • Record TCV of $6.3m up 86% vs. Q4 FY24; up 29% vs • ARR up 27% vs Q4 FY24; up 3% vs prior quarter. prior quarter. • ARR continues to grow as quarterly TCV gai
Slide 18: Revenue and Cash Receipts
Revenue and Cash Receipts Revenue Quarterly Cash Receipts A$ millions For personal use only A$ millions • Q4 FY25 revenue down 1% vs Q3 FY25. • Quarterly cash receipts of $3.8m, up 27% vs Q4 FY24. • Q4 North America revenue flat vs Q3 FY25; ROW down 19%. • Q4 operating cash outflow of $3.5m in line
Slide 19: Sales
Sales Global Installed Base ROW Installed Base Patient Tests (000s) For personal use only Units U.S. Installed base 17% 3-year CAGR1 • 44 SOZO Units Sold vs 36 Q3 FY25 • 74,000 Patient Tests in Q4 FY25 • US units sales increase by 100% to 44 units from 22 in Q3 FY25 • 0 ROW units in Q4 FY25 vs 14 in
Slide 20: Outlook for H1 FY26
For personal use only Outlook for H1 FY26 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 19 ©2025 ImpediMed Limited.
Slide 21: Outlook for H1 FY26
Outlook for H1 FY26 ❑ Grow US sales leveraging changes to sales team and expanded reimbursement For personal use only o Continue to initiate Lymphoedema awareness activities to generate leads o Further measured investment to accelerate sales strategy o Drive improvement in sales metrics o Fill remai
Slide 22: For personal use only
impedimed’ Ajuo asn jeuosiad 4104 2